Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment

Cancer Research

Volumn 56, Issue 24, 1996, Pages 5666-5671

  Nishinaka, Yumiko ^a   Ravindranath, Mepur H ^a   Irie, Reiko F ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM2;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MELANOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; EPITOPES; G(M2) GANGLIOSIDE; HUMANS; IMMUNOTHERAPY; MELANOMA; TUMOR CELLS, CULTURED;

EID: 0029768631     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. M2 as a human tumor antigen (OFA-I-1) Proc. Natl. Acad Sci. USA, 80: 5392-5396, 1983.
2. Tsuchida, T., Saxton, R E., Morton, D. L , and Irie. R. F Gangliosides of human melanoma. J. Natl. Cancer Inst., 78: 45-54, 1987.
3. Hamilton, W. B., Helling, F., Lloyd, K. O., and Livingston, P. O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer. 55: 566-573, 1993.
4. M2 in sera and tumor tissues of hepatoma patients. Jpn J Cancer Res , 78: 1309-1313, 1987.
5. Irie, R. F., and Ravindranath, M H. Gangliosides as targets for monoclonal antibody therapy of cancer In: C Borrebaech and J. Larrick (eds.), Therapeutic Monoclonal Antibody, pp. 75-94 New York: Stockton Press, 1990.
6. D2. Proc. Natl. Acad Sci. USA, 83: 8694-8698, 1986.
7. D3 ganglioside: a Phase I trial in patients with malignant melanoma. Proc Natl. Acad. Sci. USA, 82: 1242-1246, 1985.
8. D3 ganglioside in patients with melanoma induction of inflammatory responses at tumor sites. J. Clin. Oncol. 6: 1636-1648, 1988.
9. Bajorin, D F , Chapman, P. B., Wong, G., Coit, D. G., Kunicka, J., Dimaggio, J., Cordon-Cardo, C., Urmacher, C., Dantes, L , Templeton, M. A., Liu, J., Oettgen, H. F., and Houghton, A. N Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res . 50. 7490-7495, 1990.
10. Cheung, N K., Burch, L , Kushner, B. H., and Munn, D H. Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: a Phase II trial. Prog. Clin. Biol. Res., 366: 395-400, 1991.
11. D2 antibody 14G2a in metastatic melanoma. Cancer Res , 52 4342-4347, 1992.
12. D2 monoclonal antibody ch14.18 in patients with malignant melanoma Hum. Antib. Hybrid, 3: 19-24, 1992.
13. D2 antibody 14G2a Cancer Immunol. Immunother , 35: 199-204, 1992.
14. Murray, J. L , Cunningham, J E , Brewer, H , Mujoo, K., Zukiwski, A A , Podoloff, D. A , Kasi, L P , Bhadkamkar, V , Fritsche, H A., Benjamin, R. S., Legha, S. S., Ater, J. L., Jaffe, N , Itoh, K., Ross, M. I., Bucana, C. D , Thompson, L., Cheung, L , and Rosenblum, M G. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J. Clin. Oncol., 12: 184-193, 1994.
15. D2 antibody ch14 18 in patients with neuroblastoma. Eur J. Cancer. 31. 261-267, 1995.
16. D2. Proc. Natl Acad Sci USA, 79: 7629-7633, 1982.
17. Irie, R F., Sze, L. L , and Saxton, R. E Human antibody to OFA-I, a tumor antigen produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines. Proc Natl Acad Sci USA, 79: 5666-5670, 1982.
18. M3 antigen on human cancers Cancer Res., 53; 5244-5250, 1993.
19. D2 in cancer patients J Natl Cancer Inst., 73: 627-633, 1984
20. Ravindranath, M. H., Ravindranath, R M. H., Morton, D L , and Graves, M. C Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA J Immunol. Methods. 169: 257-272, 1994.
21. DIe) in various rat ascites hepatoma cells FEBS Lett., 198: 66-70, 1986.
22. O'Shannessy, D. J., and Quarles, R. H. Specific conjugation reactions of the oligosaccharide moieties of immunoglobulins. J. Appl Biochem , 7: 347-355, 1985
23. O'Shannessy, D. J., and Quarles, R. H. Labeling of the oligosaccharide moieties of immunoglobulins J Immunol Methods, 99: 153-161, 1987.
24. D2): potential for suppression of melanoma occurrence In: M. Torisu and T. Yoshida (eds.), Basic Mechanisms and Clinical Treatment of Tumor Metastases, pp. 371-384. San Diego, CA: Academic Press, 1984
25. M2: characterization of cell surface reactivity. Cancer Res., 46. 4116-4120, 1986.
26. M2-rich cultures of a human glioma cell line. Cancer Res., 51: 4643-4648, 1991.
27. M2 gangliosides. Cancer Res., 48: 6154-6160, 1988
28. D2 specificity derived from an immunized melanoma patient. Proc. Natl. Acad. Sci USA, 87: 3333-3337, 1990
29. Ando, S., Chang, N-C., and Yu, R K. High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. Anal. Biochem , 89: 437-450, 1978.
30. Nagai, Y , and Iwamori, M. Ganglioside distribution at different levels of organization and its biological implications. In: R. W Ledeen, R. K. Yu, M. M Rapport, and K. Suzuki (eds.), Ganglioside Structure, Function, and Biomedical Potential, Vol. 174, pp 135-146 New York: Plenum Press, 1984.
31. M3-ganglioside. Glycoconj. J., 6: 551-560, 1989
32. Nudelman, E., Hakomori, S., Kannagi, R., Levery, S , Yeh, M. Y., Hellström, K. E., and Hellström, I. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody. 4.2 J. Biol. Chem., 257: 12752-12756, 1982.
33. M2 antibody KM966 with brain tumors. Anticancer Res , 14: 2577-2582, 1994.
34. Hakomori, S. General concept of tumor-associated carbohydrate antigens: their chemical, physical, and enzymatic basis. In: H. F. Oettgen (ed), Gangliosides and Cancer, pp. 57-67 New York: VCH Publishers, 1989.
35. D2. Br. J. Cancer, 60: 861-866, 1989.
36. Tettamanti, G An outline of ganglioside metabolism. In: R W. Ledeen, R. K. Yu, M M. Rapport, and K. Suzuki (eds), Ganglioside Structure, Function, and Biomedical potential, Vol. 174, pp. 197-211. New York, Plenum Press, 1984
37. Morton, D L., Foshag, J., Hoon, D. S. B , Nizze, J A., Wanek, L. A., Chang, C. Davtyan, D. G., Gupta, R K , Elashoff, R , and Irie, R F Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg., 216 463-482, 1992
38. Livingston, P O. Approaches to augmenting the immunogemcity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines Immunol Rev, 145: 147-166, 1995
39. M2 for melanoma treatment. Lancet, 8641: 786-788, 1989.